

Tanaya Shree

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7513181/publications.pdf>

Version: 2024-02-01

23
papers

1,411
citations

932766

10
h-index

940134

16
g-index

23
all docs

23
docs citations

23
times ranked

2477
citing authors

#	ARTICLE	IF	CITATIONS
1	IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. <i>Genes and Development</i> , 2010, 24, 241-255.	2.7	594
2	Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. <i>Genes and Development</i> , 2011, 25, 2465-2479.	2.7	454
3	Regulation of Dopaminergic Loss by Fas in a 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2004, 24, 2045-2053.	1.7	122
4	Identification and pre-clinical testing of a reversible cathepsin protease inhibitor reveals anti-tumor efficacy in a pancreatic cancer model. <i>Biochimie</i> , 2010, 92, 1618-1624.	1.3	53
5	Single-cell analysis can define distinct evolution of tumor sites in follicular lymphoma. <i>Blood</i> , 2021, 137, 2869-2880.	0.6	48
6	Interaction of the c-Jun/JNK Pathway and Cyclin-dependent Kinases in Death of Embryonic Cortical Neurons Evoked by DNA Damage. <i>Journal of Biological Chemistry</i> , 2002, 277, 35586-35596.	1.6	40
7	CD20-Targeted Therapy Ablates <i>De Novo</i> Antibody Response to Vaccination but Spares Preestablished Immunity. <i>Blood Cancer Discovery</i> , 2022, 3, 95-102.	2.6	36
8	Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1664-1675.	0.8	20
9	Intratumoral immunotherapy relies on B and T cell collaboration. <i>Science Immunology</i> , 2022, 7, .	5.6	17
10	PARP14 is a novel target in STAT6 mutant follicular lymphoma. <i>Leukemia</i> , 2022, 36, 2281-2292.	3.3	11
11	Site to Site Comparison of Follicular Lymphoma Biopsies By Single Cell RNA Sequencing. <i>Blood</i> , 2019, 134, 297-297.	0.6	5
12	Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective <i>in Situ</i> Vaccination in Patients with Low-Grade B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 48-48.	0.6	3
13	Can B cell-deficient patients rely on COVID-19 vaccine-induced T cell immunity?. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
14	Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. <i>Cancer Cytopathology</i> , 2022, 130, 231-237.	1.4	2
15	Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing <i>in Situ</i> Vaccination. <i>Blood</i> , 2020, 136, 36-37.	0.6	1
16	Abstract LB-379: IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasion. , 2010, , .		1
17	A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2825-2825.	0.6	1
18	Abstract 549: Sensitization to chemotherapy by inhibition of cathepsin proteases in a mouse model of metastatic breast cancer. , 2011, , .		0

#	ARTICLE	IF	CITATIONS
19	Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma. <i>Blood</i> , 2018, 132, 1612-1612.	0.6	0
20	Dynamic Immune Modulation Seen By Single Cell RNA-Sequencing of Serial Lymphoma Biopsies in Patients Undergoing in Situ Vaccination. <i>Blood</i> , 2019, 134, 1479-1479.	0.6	0
21	Therapeutic and Immunologic Responses Elicited By in Situ Vaccination with CpG, Ibrutinib, and Low-Dose Radiation. <i>Blood</i> , 2021, 138, 3539-3539.	0.6	0
22	<i>In Situ</i> Vaccination Induces Changes in Follicular Lymphoma Tumor Cells That Correlate with Abscopal Clinical Regressions. <i>Blood</i> , 2021, 138, 2407-2407.	0.6	0
23	Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 2064-2064.	0.6	0